Jump to content

Search the Community

Showing results for tags 'news'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • HOPE
    • GRIEF


  • An Advocates Perspective
  • Cheryncp123's Blog
  • Stay The Course
  • Lung Cancer Stories
  • Spree
  • Volunteer Voices
  • Caregivers Connection
  • Stage IV Treatment With S.B.R.T.
  • Susan Cornett
  • Robin S
  • Lung Cancer & Health Insurance: Tips on managing the mayhem.
  • Daze of My Life by Ken Lourie
  • CommUNITY Connection
  • Heather Smith
  • Lisa Haines
  • Veteran's Oprions
  • Cancer: holding his hand until his last breath
  • A Healthy Place
  • Lenny Blue
  • The Roscopal Effect
  • Ro
  • Sharron P
  • Loi ich suc khoe cua qua chi tu
  • Shanesga
  • Facts are stubborn things, but statistics are pliable

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...


  • Start



First name

Last name


Province or district (if non-US)

Postal code



Found 16 results

  1. Here is the weekly clip report: Cure “Lung Cancer Care Becoming More Personalized and Trials will Too” https://www.curetoday.com/articles/lung-cancer-care-becoming-more-personalized-and-trials-will-too Cancer Therapy Advisor “Lurbinectedin Receives FDA Orphan Drug Status for Recurrent Small-Cell Lung Cancer” https://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-nsclc-lurbinecedin-fda-oprhan-drug-status-treatment/article/786009/ U.S. News – Health “What to Know about Lung Cancer Screening Guidelines” https://www.nga.org/governors/addresses/ Healio “Minimally Invasive Surgery Effective for Early-Stage Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{924a7fc0-fcda-4ffb-bad7-4f2cb101c1db}/minimally-invasive-surgery-effective-for-early-stage-lung-cancer Onc Live “Dr. Witsuba on Biomarkers for Immunotherapy in Lung Cancer” https://www.onclive.com/onclive-tv/dr-wistuba-on-biomarkers-for-immunotherapy-in-lung-cancer Drug Target Review “Reducing NOVA1 Helps prevents Tumour Growth in Lung Cancer” https://www.drugtargetreview.com/news/34089/reducing-nova1-lung-cancer/ Science Daily “Finally, a Potential New Approach against KRAS-Driven Lung Cancer” https://www.sciencedaily.com/releases/2018/08/180809093458.htm Oncology Nurse Advisor “New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab” https://www.oncologynurseadvisor.com/lung-cancer/pdl1-inhibitors-for-nsclc-focus-on-pembrolizumab/article/787627/
  2. Here is the weekly clip report: U.S. News & World Report "From the 'Big C' to Cancer" https://health.usnews.com/health-care/patient-advice/articles/2018-03-21/from-the-big-c-to-cancer Healio “Lower-Limb Arterial Thrombosis May Be Marker of Cancer” https://www.healio.com/cardiac-vascular-intervention/peripheral/news/online/{f342b55f-87eb-4edc-a0eb-608633079467}/lower-limb-arterial-thrombosis-may-be-marker-of-cancer Medscape “How to Improve Diversification of Patients with Cancer in Clinical Trials” https://www.medscape.com/viewarticle/894210 Oncology Nursing News "New Treatments for Lesser-Known Targets in NSCLC Are Emerging" http://www.oncnursingnews.com/web-exclusives/new-treatments-for-lesserknown-targets-in-nsclc-are-emerging Smithsonian Magazine “Could Immunotherapy Lead the Way to Fighting Cancer?” https://www.smithsonianmag.com/innovation/immunotherapy-lead-way-fighting-cancer-180968392/ Medscape “From ALK to T790M: The Role of Liquid Biopsy in Lung Cancer” https://www.medscape.com/viewarticle/894215 Medical Xpress “RNA-Based Therapeutic Inhibits a Metabolic Pathway in Tumor-Initiating Lung Cancer Cells” https://medicalxpress.com/news/2018-03-rna-based-therapeutic-inhibits-metabolic-pathway.html Bloomberg “Robots Could Replace Surgeons in the Battle Against Cancer” https://www.bloomberg.com/news/features/2018-03-23/robots-could-replace-surgeons-in-the-battle-against-cancer
  3. WASHINGTON, DC (March 14, 2018) — LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, today announced that Andre Owens, partner in the Washington, D.C., law office of WilmerHale, has joined the Board of Directors. Together with other global leaders on the Board, Owens will lend his expertise to further LUNGevity’s work of changing outcomes for people with lung cancer. “We are grateful to have someone as uniquely qualified as Andre join our Board,” said Andrea Ferris, CEO of LUNGevity Foundation. “His valuable specialized knowledge coupled with a strong personal motivation for increasing survivorship in lung cancer makes Andre a great addition to help steer the Foundation’s research, education, support, and public policy programs.” “Like so many others, I have been personally affected by the loss of loved ones to lung cancer,” explains Owens. “While there has been some progress in the lung cancer space, we still have a lot more to do. I am proud and honored to help LUNGevity achieve its vision of creating a world where no one dies of lung cancer.” Andre’s legal practice focuses on securities trading and markets activities. He counsels broker-dealers, securities exchanges, investment advisers, and other clients on a variety of regulatory issues. In the past, Andre served as a member of the U.S. Securities and Exchange Commission’s Office of General Counsel. He also served as counsel to former SEC Commissioner Steven M. H. Wallman. Mr. Owens graduated from Providence College with a bachelor’s degree and holds a JD degree from Harvard Law School. Read the full press release.
  4. Here is the weekly clip report: WRC-TV “Exhibitors Guide: Full List of Exhibitors at the 2018 Health and Fitness Expo” https://www.nbcwashington.com/news/health/Exhibitors-Guide-Full-List-Exhibitors-Health-and-Fitness-Expo-474441813.html Immuno-Oncology News “Bristol-Myers, Nektar Developing Cancer Therapy to Be Used with Checkpoint Inhibitors” https://immuno-oncologynews.com/2018/02/26/bristol-myers-squibb-nektar-cancer-immunotherapy-checkpoint-inhibitors/ Color.com – Blog/Podcast “Adam Klein, Winner of 2016 Survivor, on Becoming a Leading Lung Cancer Advocate” https://blog.color.com/adam-klein-winner-of-2016-survivor-on-becoming-a-leading-lung-cancer-advocate-f2ca8f48415 OncLive “Expert Highlights Immunotherapy Use in Stage III NSCLC” http://www.onclive.com/web-exclusives/expert-highlights-immunotherapy-use-in-stage-iii-nsclc OncLive “Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLC” http://www.onclive.com/onclive-tv/dr-gieschen-on-the-side-effects-of-radiation-therapy-in-nsclc The Baltimore Sun “Orioles Notes: Lee Expected to Miss Four Weeks; Hays to Get Break with Bum Shoulder” http://www.baltimoresun.com/sports/orioles/blog/bs-sp-orioles-notes-20180301-story.html Genome Web “As Cancer Immunotherapy Evolves, Challenges Compound for Diagnostic Development” https://www.genomeweb.com/molecular-diagnostics/cancer-immunotherapy-evolves-challenges-compound-diagnostic-development Cure Today “Taking Action to Address Lung Cancer Across the US” https://www.curetoday.com/articles/taking-action-to-address-lung-cancer-across-the-us Virginia Business "50 Most Influential Virginians - Lynne Doughtie" http://www.virginiabusiness.com/news/article/50-most-influential-virginians-2018
  5. Hi, SMAs, Here is the weekly clip report: Healio “Targeted Radiation Reduces Mortality for Early-Stage Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/in-the-journals/{ea2da7d0-cbee-4aba-bba7-5028dde05d69}/targeted-radiation-reduces-mortality-for-early-stage-lung-cancer OncLive “ALK Inhibitors Continue to Reshape Treatment in NSCLC” http://www.onclive.com/web-exclusives/alk-inhibitors-continue-to-reshape-treatment-in-nsclc U.S. News & World Report “Are More People Dying of Cancer?” https://health.usnews.com/health-care/patient-advice/articles/2018-02-20/are-more-people-dying-of-cancer Women’s Health “’How I Told My Siblings I Had Lung Cancer’” https://www.womenshealthmag.com/health/a18377542/lung-cancer-diagnosis/ OncLive “Clinical Trials Highlight Biomarker Progress in Lung Cancer” http://www.onclive.com/web-exclusives/clinical-trials-highlight-biomarker-progress-in-lung-cancer Clinical Oncology “Imfinzi Granted New Indication to Reduce Risk for NSCLC Progression” http://www.clinicaloncology.com/FDA-Watch/Article/02-18/Imfinzi-Granted-New-Indication-to-Reduce-Risk-for-NSCLC-Progression/47007 OncLive “Larotrectinib Update Shows Durable Responses in TRK-Positive Cancers” http://www.onclive.com/web-exclusives/larotrectinib-update-shows-durable-responses-in-trkpositive-cancers Cancer Therapy Advisor “Phase 2 Trial of AZD1775 for Squamous Cell Lung Cancer” https://www.cancertherapyadvisor.com/lung-cancer/azd1775-squamous-cell-lung-cancer-phase-2-trial/article/746115/ BBC News “Mini-Tumors’ Created to Battle Cancer” http://www.bbc.com/news/health-43154878 Medical Xpress “An Under-the-Radar Immune Cell Shows Potential in Fight Against Cancer” https://medicalxpress.com/news/2018-02-under-the-radar-immune-cell-potential-cancer.html GenomeWeb “New Extracellular Particle Could Prove Useful for Cancer Diagnosis, Monitoring” https://www.genomeweb.com/proteomics-protein-research/new-extracellular-particle-could-prove-useful-cancer-diagnosis
  6. Here is the weekly clip report: USA Today “Bristol-Myers Squibb Claims ‘Breakthrough’ Lung Cancer Treatment” https://www.usatoday.com/story/money/2018/02/05/bristol-myers-squibb-claims-breakthrough-lung-cancer-treatment/306433002/ Forbes “Genprex Launch IPO for Trials of New Gene Therapy Lung Cancer Treatment” https://www.forbes.com/sites/rodnturner/2018/02/05/genprex-launch-ipo-for-trials-of-new-gene-therapy-lung-cancer-treatment/#167f00d449fd Cure Today “Not All Small-Cell Lung Cancer Treatment is Equal” https://www.curetoday.com/articles/not-all-small-cell-lung-cancer-treatment-is-equal Targeted Oncology “Gray Sheds Light on Considerations When Treating NSCLC with Immunotherapy” http://www.targetedonc.com/news/gray-sheds-light-on-considerations-when-treating-nsclc-with-immunotherapy Oncology Nurse Advisor “Lung Cancer Screening: Risk-Targeting Approach vs NLST Eligibility Criteria” https://www.oncologynurseadvisor.com/lung-cancer/risk-targeting-approach-vs-national-lung-screening-trial-eligibility-criteria/article/741924/ OncLive “Dr. Erhunmwunsee on Factors of Disparity in Lung Cancer Treatment” http://www.onclive.com/onclive-tv/dr-erhunmwunsee-on-factors-of-disparity-in-lung-cancer-treatment News Medical “LUNGevity Foundation Launches Initiative to Promote Stronger Adherence to Lung Cancer Screening” https://www.news-medical.net/news/20180207/LUNGevity-Foundation-launches-initiative-to-promote-stronger-adherence-to-lung-cancer-screening.aspx Healio “ASCO Panel: Precision Medicine in Practice Can Be Challenging” https://www.healio.com/hematology-oncology/practice-management/news/online/{29cffa20-1d9b-41e1-84e1-804341997d73}/asco-panel-precision-medicine-in-practice-can-be-challenging The Daily Telescope “Dr. Julie Brahmer, M.D., M.Sc. Is Named Professional of the Year by the International Assoc. of Who’s Who” http://dailytelescope.com/pr/dr-julie-r-brahmer-m-d-m-sc-is-named-professional-of-the-year-by-the-international-assoc-of-whoaes-who/66790 UCLA Health “A Double Dose of Promising Lung Cancer Findings” https://www.uclahealth.org/u-magazine/body.cfm?id=17&action=detail&ref=1137 NPR “What Not to Say to the Terminally Ill: ‘Everything Happens for a Reason’” https://www.npr.org/sections/health-shots/2018/02/08/583774624/what-not-to-say-to-the-terminally-ill-everything-happens-for-a-reason
  7. Here is the weekly clip report: PR Newswire “American College of Chest Physicians Publishes New Lung Cancer Screening Guidelines” https://www.prnewswire.com/news-releases/american-college-of-chest-physicians-publishes-new-lung-cancer-screening-guidelines-300589650.html The ASCO Post “Durvalumab Takes a Giant Leap into Stage III NSCLC” http://www.ascopost.com/issues/january-25-2018/durvalumab-takes-a-giant-leap-into-stage-iii-nsclc/ EurekAlert! “New Radiation Techniques Could Improve Quality of Life for Lung Cancer Patients” https://www.eurekalert.org/pub_releases/2018-01/lhri-nrt012918.php Medical Xpress “Expert Panel Issues New Guidelines for Lung Cancer Molecular Testing” https://medicalxpress.com/news/2018-01-expert-panel-issues-guidelines-lung.html KETV-TV “Radon Awareness Month: Lung Cancer Survivor Thinks Radon Caused It” http://www.ketv.com/article/radon-awareness-month-lung-cancer-survivor-thinks-radon-caused-it/15893580 Oncology Nursing News “Socioeconomic Disparity in Lung Cancer Care” http://www.oncnursingnews.com/web-exclusives/socioeconomic-disparity-in-lung-cancer-care OncLive “Treatment of Locally Advanced NSCLC” http://www.onclive.com/insights/multimodal-advanced-nsclc/treatment-of-locally-advanced-nsclc OncLive “Treatment of Early-Stage NSCLC” http://www.onclive.com/insights/multimodal-advanced-nsclc/treatment-of-early-stage-nsclc Cure Today “Who Wears the Face of Cancer?” https://www.curetoday.com/community/bonnie-annis/2018/01/who-wears-the-face-of-cancer Pittsburgh Post-Gazette “LUNGevity Foundation Announces Initiative to Save Lives Through Increased Adherence to Lung Cancer Screening” http://markets.post-gazette.com/postgazette/news/read/35699542/lungevity_foundation_announces_initiative_to_save_lives_through_increased_adherence_to_lung_cancer_screening EurekAlert! “Small Molecule Plays a Big Role in Reducing Cancer’s Spread” https://www.eurekalert.org/pub_releases/2018-01/mcog-smp013018.php KIMT-TV “Lung Cancer Survivor Heads to Super Bowl 52” http://www.kimt.com/content/news/Lung-cancer-survivor-heads-to-Super-Bowl-52-471847253.html The New York Times “After a Cancer Diagnosis, Playing the Odds” https://www.nytimes.com/2018/01/31/well/live/after-a-cancer-diagnosis-playing-the-odds.html Targeted Oncology “Will Combination Therapy with Immunotherapy Become the New Standard of Care for NSCLC?” http://www.targetedonc.com/news/will-combination-therapies-with-immunotherapy-become-the-new-standard-of-care-for-nsclc MIT News “Fine-Tuning Cancer Medicine” http://news.mit.edu/2018/fine-tuning-cancer-medicine-0201 Medical Xpress “Early Access to Palliative Care Associated with Better Quality of Life” https://medicalxpress.com/news/2018-02-early-access-palliative-quality-life.html Medical Xpress “Clinical Trial Tests Feasibility of Targeting Particular Classes of Tumor Types with Certain Drugs” https://medicalxpress.com/news/2018-02-clinical-trial-feasibility-classes-tumor.html
  8. Here is the weekly clip report: PR Newswire “LUNGevity Foundation Kicks Off New Public Service Campaign to Alter View of Lung Cancer Diagnosis” https://www.prnewswire.com/news-releases/lungevity-foundation-kicks-off-new-public-service-campaign-to-alter-view-of-lung-cancer-diagnosis-300583589.html Baylor College of Medicine “Immunotherapy Treatment Gives Lung Cancer Patient Second Chance” https://blogs.bcm.edu/2018/01/22/immunotherapy-treatment-gives-lung-cancer-patient-second-chance/ Variety “Allison Shearmur, ‘Rogue One,’ “Hunger Games’ Producer, Dies at 54” http://variety.com/2018/film/news/allison-shearmur-dead-dies-star-wars-hunger-games-1202670745/ South Fine Arts Blog “LUNGEVITY Arts Coffee House” http://southfinearts.blogspot.com/ EurekAlert! “Leading Medical Organizations Update Lung Cancer Guideline” https://eurekalert.org/pub_releases/2018-01/iaft-lmo012318.php PR Newswire “Biomarck Announces the Start of a Phase 2 Clinical Trial of BIO-11006 for Non-Small Cell Lung Cancer (NSCLC)” https://www.prnewswire.com/news-releases/biomarck-announces-the-start-of-a-phase-2-clinical-trial-of-bio-11006-for-non-small-cell-lung-cancer-nsclc-300586095.html Cleveland Clinic “Immunotherapy Triggers New Lease on Life for Lung Cancer Patients” https://newsroom.clevelandclinic.org/2018/01/22/immunotherapy-triggers-new-lease-on-life-for-lung-cancer-patient/ OncLive “Dr. Garon on Sequencing of Agents for Advanced Lung Cancer” http://www.onclive.com/onclive-tv/dr-garon-on-sequencing-of-agents-for-advanced-lung-cancer EurekAlert! “International Organizations Partner to Spread Awareness of Revised Lung Cancer Staging Criteria” https://www.eurekalert.org/pub_releases/2018-01/iaft-iop012318.php University of Chicago Medicine “Targeted Treatments Halt Spread of Advanced Non-Small Cell Lung Cancer” https://www.uchicagomedicine.org/cancer-articles/targeted-treatments-halt-spread-of-advanced-non-small-cell-lung-cancer HealthDay “New Treatments Tackling Tough Lung Cancer” https://consumer.healthday.com/cancer-information-5/lung-cancer-news-100/new-treatments-tackling-tough-lung-cancer-730442.html Cancer Therapy Advisor “Lung Cancer: FDA Collaboration Highlights Real-World Immunotherapy Treatment Patterns” https://www.cancertherapyadvisor.com/lung-cancer/lung-cancer-fda-collaboration-immunotherapy-treatment-patterns/article/739081/ The ASCO Post “Ceritinib in ALK-Positive Metastatic Non-Small Cell Lung Cancer” http://www.ascopost.com/issues/january-25-2018/ceritinib-in-alk-positive-metastatic-non-small-cell-lung-cancer/
  9. Here is the weekly clip report: The ASCO Post “Stand Up To Cancer Launches ‘Cancer Interception’ Teams to Detect and Treat Cancer at Earliest Stages” http://www.ascopost.com/issues/november-25-2017/stand-up-to-cancer-launches-cancer-interception-teams-to-detect-and-treat-cancer-at-earliest-stages/ Stanford Medicine News Center “Stanford Scientists among Those Funded by Stand Up To Cancer” https://med.stanford.edu/news/all-news/2017/11/stanford-scientists-among-those-funded-by-stand-up-to-cancer.html Immuno-Oncology News “Imfinzi Increases Time for Non-Small Cell Lung Cancer to Progress, Phase 3 Trial Shows” https://immuno-oncologynews.com/2017/11/28/phase-3-trial-shows-imfinzi-lengthens-time-for-non-small-cell-lung-cancer-to-return/ Targeted Oncology “Ahead of NSCLC Approval Decision, FDA Now Weighing Durvalumab Data in NEJM” http://www.targetedonc.com/news/ahead-of-nsclc-approval-decision-fda-now-weighing-durvalumab-data-in-nejm OncLive “Immunotherapy to Have Emerging Role in Squamous Cell Lung Cancer” http://www.onclive.com/web-exclusives/immunotherapy-to-have-emerging-role-in-squamous-cell-lung-cancer Business Wire “Impassioned Lung Cancer Survivors Join Your Cancer Game Plan, Merck to Advocate for Others Facing This Highly Stigmatized Disease” http://www.businesswire.com/news/home/20171129005025/en/Impassioned-Lung-Cancer-Survivors-Join-Cancer-Game The Baltimore Sun “Life After Lung Cancer: How One Survivor is Fighting for Others” http://www.baltimoresun.com/bp/blt-ara-31849-life-after-lung-cancer-how-one-survivor-is-fighting-for-others-20171129-adstory.html National Press Club “Life After Cancer: Addressing Survivorship in Cancer Care” http://www.press.org/events/life-after-cancer-addressing-survivorship-cancer-care Markets Insider “Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept’s Liquid Biopsy Test in Immunotherapy” http://markets.businessinsider.com/news/stocks/Biocept-and-UC-San-Diego-Medical-Center-Announce-Clinical-Study-Collaboration-to-Demonstrate-Utility-of-Biocept-s-Liquid-Biopsy-Test-in-Immunotherapy-1009786790 Medical Xpress “Two-Drug Combination May Boost Immunotherapy Response in Lung Cancer Patients” https://medicalxpress.com/news/2017-11-two-drug-combination-boost-immunotherapy-responses.html Reuters “FDA Aims to Approve More Drugs Based on Early Clinical Data” https://www.reuters.com/article/us-fda-hearing-testimony/fda-aims-to-approve-more-drugs-based-on-early-clinical-data-idUSKBN1DU2DS Healio “Eight Important Updates in Lung Cancer” https://www.healio.com/hematology-oncology/lung-cancer/news/online/{56102e9b-63d2-4eea-8859-01b452dbe2b3}/eight-important-updates-in-lung-cancer Investor’s Business Daily “This Biotech Launched to a Record High on Cancer Test Approval” https://www.investors.com/news/technology/this-biotech-launched-to-a-record-high-on-cancer-test-approval/ DOD Congressionally Directed Medical Research Programs “Melissa Crouse – Lung Cancer Warrior, Mentor and Advocate” http://cdmrp.army.mil/cwg/stories/2017/melissa_crouse_profile Business Wire “FDA Approves Foundation Medicine’s FoundationOne Cdx, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics” http://www.businesswire.com/news/home/20171130006320/en/FDA-Approves-Foundation-Medicine’s-FoundationOne-CDx™-Comprehensive Markets Insider “Advocates Reveal Cancer Survivorship Challenges and Resources During National Comprehensive Cancer Network’s Patient Advocacy Summit” http://markets.businessinsider.com/news/stocks/Advocates-Reveal-Cancer-Survivorship-Challenges-and-Resources-during-National-Comprehensive-Cancer-Network-s-Patient-Advocacy-Summit-1010204005
  10. Here is the weekly clip report, including two big announcements from LUNGevity: MedCity News “A Snapshot of Personalized Medicine in Practice” https://medcitynews.com/2017/10/snapshot-personalized-medicine-practice/ PR Newswire “Alexander F. Stern Named Chairman of the Board of LUNGevity Foundation” http://www.prnewswire.com/news-releases/alexander-f-stern-named-chairman-of-the-board-of-lungevity-foundation-300533962.html Markets Insider “Marc Swerdlow Named Vice-Chairman and Treasurer of the Board of LUNGevity Foundation” http://markets.businessinsider.com/news/stocks/Marc-Swerdlow-named-Vice-Chairman-and-Treasurer-of-the-Board-of-LUNGevity-Foundation-1003678880 Cure Today “Tagrisso Approved for Frontline Lung Cancer Treatment” http://www.curetoday.com/articles/tagrisso-approved-for-frontline-lung-cancer-treatment Medical News Bulletin “Can Genetic Screening Improve Lung Cancer Prognoses?” https://www.medicalnewsbulletin.com/gene-screening-lung-cancer-prognoses/ Cure Today “Personalized Treatment Needed for Advanced Lung Cancer” http://www.curetoday.com/articles/personalized-treatment-needed-for-advanced-lung-cancer Medical Xpress “A New Class of Drugs Aims to Exploit Cancer Cells’ Weaknesses” https://medicalxpress.com/news/2017-10-class-drugs-aims-exploit-cancer.html PR Newswire “Stand Up To Cancer Awards Moffitt $2.67 Million to Study New Lung Cancer Immunotherapy” http://www.prnewswire.com/news-releases/stand-up-to-cancer-awards-moffitt-267-million-to-study-new-lung-cancer-immunotherapy-300535599.html Los Angeles Times “Curing Cancer Isn’t Always the Goal. Sometimes You Just Want It to Be a Manageable Chronic Disease” http://www.latimes.com/science/healthy-living/la-he-hl-cancer-cure-20171012-story.html Los Angeles Times “With Cancer, It’s Not Necessarily Where It Starts but Hot It Starts” http://www.latimes.com/science/healthy-living/la-he-hl-cancer-genetics-organ-20171012-story.html The Wall Street Journal “Immunotherapy Treatments for Cancer Gain Momentum” https://www.wsj.com/articles/immunotherapy-treatments-for-cancer-gain-momentum-1507825152
  11. LUNGevity Foundation's Career Development Awards (CDA) for lung cancer research fund critical lung cancer research projects and offer the recipients world-class mentorship by LUNGevity’s prestigious Scientific Advisory Board. “LUNGevity created the CDAs to identify outstanding scientists early in their careers and encourage their continued development in the field of lung cancer research to grow a strong pipeline of dedicated lung cancer researchers,” says Charles Rudin, MD, PhD, Professor and Chief, Thoracic Oncology Service, at Memorial Sloan Kettering Cancer Center and chair of LUNGevity’s Scientific Advisory Board. “We work closely with these researchers with the hope of seeing them become the next generation of scientific superstars.” LUNGevity is proud to support the following researchers its 2017 Career Development Awards: Mehmet Altan, MD, The University of Texas MD Anderson Cancer Center, Identification of predictive markers of toxicity to immunotherapy. Dr. Altan will work to develop a way to predict which patients are most likely to develop serious side effects from some types of immunotherapy – these side effects can limit use of the treatments. Once patients can be flagged as high-risk for tissue damage, measures can be taken to limit the tissue damage proactively; patients may then experience better outcomes with their immunotherapy. Valsamo Anagnostou, MD, PhD, Johns Hopkins University, Dynamics of neoantigen landscape during immunotherapy in lung cancer. Dr. Anagnostou will leverage an existing clinical trial to discover why some patients become resistant to immunotherapy and to get a handle on how to help them overcome the resistance. Zofia Piotrowska, MD, Massachusetts General Hospital, Overcoming heterogeneity and resistance in EGFR-mutant NSCLC. Dr. Piotrowska intends to uncover the reason a subset of lung cancer patients develop resistance to their best option for treatment: a third-generation EGFR-blocking tyrosine kinase inhibitor drug. In addition, she will study a new combination of drugs in a clinical trial that may help patients who develop this type of drug resistance. “We have seen a lot of great progress in treating lung cancer, and we still need to better understand how lung cancer develops resistance to drugs, and why some patients experience side effects from treatment,” notes Upal Basu Roy, PhD, MPH, director of LUNGevity’s translational science research program. “Our funding this year’s group of awardees will help make progress in facing these challenges and continue to improve outcomes for lung cancer patients.” Each of these prestigious three-year awards is for $100,000 per year, renewable in the second and third years based on research progress. Awardees serve as non-voting members of LUNGevity’s distinguished Scientific Advisory Board for the terms of their awards. Awardees are mentored by senior lung cancer experts at their own institutions as well as by experts from the Scientific Advisory Board. Under the guidance of LUNGevity’s Scientific Advisory Board, a group of 21 prominent scientists and researchers, LUNGevity ensures that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives for lung cancer survivors. LUNGevity is the only lung cancer organization with a programmatic focus on early detection and a robust Career Development Award Program. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The foundation’s overall research program, including CDA awards, is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. LUNGevity’s Scientific Research Program is supported by the American Lung Association, Bristol-Myers Squibb, Genentech, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, and individual donors. Read the full press release.
  12. LUNGevity Foundation has launched Patient FoRCe, the first-ever critical bridge to connect the voices of lung cancer patients — a significant population — with health care professionals, regulators, policymakers, and developers of drugs. “Lung cancer is the #1 cancer killer, taking the lives of 157,000 Americans every year. LUNGevity is leading the way in changing the paradigm of cancer treatment ─ from assuming patient wishes to evidence-based conclusions about what patients value,” said LUNGevity Chairman Andrea Stern Ferris. “Through Patient FoRCe, lung cancer patient voices will be heard and heeded as policy is developed, research is conducted, and treatment decisions are made.” Patient FoRCe, LUNGevity’s Patient-Focused Research Center, will undertake never-before studies of those living with lung cancer, collecting and sharing robust qualitative and quantitative data about lung cancer patients’ preferences and experiences to inform treatment, as well as relevant policy and research protocols. Patient FoRCe’s immediate focus will include continuing a study of patient preferences and experiences regarding access to care, treatment and diagnostic options, and the impact of symptoms on daily living, as well as conducting studies to facilitate patients’ access to biomarker testing, which is essential to implementing precision medicine. Patient FoRCe will also initiate a study into increasing adherence to lung cancer screening protocols for people at high risk for lung cancer. Additional projects will be based on stakeholder input and the guidance of an external advisory board of survivors, academic and community clinicians, industry partners, patient advocacy groups, and community partners. LUNGevity formally announced Patient FoRCe at the American Association for Cancer Research’s 2017 Annual Meeting in Washington, DC, on Sunday, April 2. Andrea Stern Ferris spoke to the urgency of the initiative, saying, “For too long, public policy, the practice of medicine, and drug development have not adequately integrated the viewpoint of patients. LUNGevity is determined to change that paradigm. By incorporating the patient’s voice into every step of the process – in policymaking, in trials, in treatments – we will improve outcomes for those diagnosed with lung cancer.” “Our goal is to uncover gaps in information, misperceptions about patient attitudes, and areas of unmet patient need,” explained Dr. Upal Basu Roy, Director of Patient FoRCe. “LUNGevity is the only organization driving this type of change for the lung cancer community, and we anticipate that our findings will shape the future of lung cancer care.” For more information about Patient FoRCe, visit www.LUNGevity.org/patientforce. Click here to read the full press release.
  13. Edward Garon, MD, of UCLA joins the LUNGevity Foundation Scientific Advisory Board Dr. Garon brings expertise in clinical trials and other key areas to LUNGevity’s research program FOR IMMEDIATE RELEASE Media Contact: Austin Courtney acourtney@susandavis.com (202) 414-0791 WASHINGTON, DC (January 13, 2017) – LUNGevity Foundation, the nation’s preeminent lung cancer research foundation, today announced that Edward Garon, MD, has joined LUNGevity’s Scientific Advisory Board, a group of 19 world-renowned scientists and researchers who guide LUNGevity’s scientific strategy and research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific approach and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives for lung cancer survivors. LUNGevity is the only lung cancer organization with programmatic focuses on early detection and Career Development Awards. LUNGevity-funded researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. Dr. Garon is the Director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at UCLA and Associate Professor of Medicine in the Division of Hematology-Oncology at David Geffen School of Medicine at UCLA. He has been the principal investigator of peer-reviewed grants from various funding organizations, including the National Cancer Institute. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II, and III clinical trials. Among these are trials that have led to the approval of drugs for the treatment of non-small cell lung cancer, including ramucirumab (Cyramza®) and the immunotherapy pembrolizumab (Keytruda®). “We are honored that Dr. Garon has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “His expertise and advice will be invaluable to furthering LUNGevity’s goal to improve outcomes for lung cancer patients.” Click here to read the complete press release on LUNGevity.org.
  14. Looking for good resources to keep me up to date on recent advances in treatment of lung cancer. I know access to the latest is what will make the difference; I have found the daily news updates at this site to be quite useful http://news.cancerconnect.com/lung-cancer-overview/ would like to know what other sources people have found useful Thanks Maltman
  15. Good afternoon, LCSC members! Every Friday, I will start sharing a weekly clip report in this forum. I encourage you to reply to each thread to let us know what kind of news stories are most interesting/relevant to you. I'll post the first weekly clip report this Friday, December 16! With gratitude, Lauren -- Digital Community Manager LUNGevity Foundation
  16. A breakthrough study by local doctors may hold new clues to one day curing certain cancers such as lung cancer. http://www.local12.com/news/features/top-stories/stories/MONDAY-AT-6-Alive-and-thriving-188709.shtml Updated: Wed, Aug 26 2015, 12:54 AM CINCINNATI (Liz Bonis) -- A breakthrough study by local doctors may hold new clues to one day curing certain cancers such as lung cancer. A new drug recently approved for use by the FDA showed promise for patients in a whole new way. By the time Jean Pierre Heiremans, or JP as he's known, saw Dr. David Waterhouse, traditional treatment for his stage four lung cancer no longer appeared to be stopping its spread. So Dr. Waterhouse gave him the option of enrolling in a clinical trial. It was comparing a newer therapy, called Nivolumab, to another traditional treatment medication. JP didn't know if he'd be given the newer therapy but he knows if he did get it, “This to me was something that didn't have odds to it yet because it was new, there were no odds. So I could make my own odds.” JP got lucky, He not only got the newer therapy and did make his own odds, he's still making them. The study results were published in the New England Journal of Medicine and showed JP wasn't the only one! As Dr. Waterhouse showed, when they started comparing the two study groups officials saw near doubling of survival. The trial drug appeared to work by sort of altering switches on cells to help the body fight back against the cancer. And not only did it appear to double the odds of survival in some, compared to the traditional treatment for others Dr. Waterhouse discovered, “Not only were they surviving, they were living.” Some in the study, such as JP, responded so well they just kept living and thriving. They were what Dr. Waterhouse called extraordinary or super responders. “When we did this study what we saw was a large number of those extraordinary responders, that unexpected home run. And we are not sure what's going to happen in them,” said Dr. Waterhouse What was most exciting, he said, about the trial wasn’t just the amazing results; it was that it was actually changing the way people think about living with cancer. The super performers, or super responders, really let officials know that there were long term outcomes they had never had before, changing the face of cancer survivorship. “What really made the trial so important was it showed a promise down the road that there was going to be a day that doctors could cure solid tumors. JP is now more than three years out of his treatment. He's exceeded his own odds of certain milestones such as seeing his daughter get married. He said he felt he was paving the way now for others to exceed the odds too and live with cancer as they would any other chronic health problem. Read More at: http://www.local12.com/news/features/top-stories/stories/MONDAY-AT-6-Alive-and-thriving-188709.shtml
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.